Efficient Heat Shock Response Affects Hyperthermia-Induced Radiosensitization in a Tumor Spheroid Control Probability Assay.

head and heck squamous cell carcinomas (HNSCC) heat shock proteins (Hsps) hyperthermia proteotoxic stress radiation therapy spheroids

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
25 Jun 2021
Historique:
received: 29 04 2021
revised: 21 06 2021
accepted: 22 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

Hyperthermia (HT) combined with irradiation is a well-known concept to improve the curative potential of radiotherapy. Technological progress has opened new avenues for thermoradiotherapy, even for recurrent head and neck squamous cell carcinomas (HNSCC). Preclinical evaluation of the curative radiosensitizing potential of various HT regimens remains ethically, economically, and technically challenging. One key objective of our study was to refine an advanced 3-D assay setup for HT + RT research and treatment testing. For the first time, HT-induced radiosensitization was systematically examined in two differently radioresponsive HNSCC spheroid models using the unique in vitro "curative" analytical endpoint of spheroid control probability. We further investigated the cellular stress response mechanisms underlying the HT-related radiosensitization process with the aim to unravel the impact of HT-induced proteotoxic stress on the overall radioresponse. HT disrupted the proteome's thermal stability, causing severe proteotoxic stress. It strongly enhanced radiation efficacy and affected paramount survival and stress response signaling networks. Transcriptomics, q-PCR, and western blotting data revealed that HT + RT co-treatment critically triggers the heat shock response (HSR). Pre-treatment with chemical chaperones intensified the radiosensitizing effect, thereby suppressing HT-induced Hsp27 expression. Our data suggest that HT-induced radiosensitization is adversely affected by the proteotoxic stress response. Hence, we propose the inhibition of particular heat shock proteins as a targeting strategy to improve the outcome of combinatorial HT + RT.

Identifiants

pubmed: 34201993
pii: cancers13133168
doi: 10.3390/cancers13133168
pmc: PMC8269038
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : German Federal Ministry of Education and Research
ID : 03Z1N51

Références

Int J Hyperthermia. 2008 Feb;24(1):3-15
pubmed: 18214765
Oncotarget. 2016 Oct 18;7(42):68156-68169
pubmed: 27626687
Radiat Oncol. 2015 Aug 07;10:165
pubmed: 26245485
Radiat Res. 1978 Aug;75(2):373-84
pubmed: 715179
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
Recent Pat Anticancer Drug Discov. 2017;12(1):35-47
pubmed: 27809750
Cancer Treat Rev. 2015 Nov;41(9):742-53
pubmed: 26051911
Front Oncol. 2020 Jun 12;10:819
pubmed: 32596144
Radiother Oncol. 2010 Jul;96(1):116-22
pubmed: 20570380
Sci Rep. 2019 Nov 27;9(1):17674
pubmed: 31776398
Trends Biochem Sci. 2016 Apr;41(4):311-323
pubmed: 26874923
Exp Cell Res. 2016 Feb 1;341(1):67-74
pubmed: 26751966
Cell Death Dis. 2019 Jul 15;10(8):540
pubmed: 31308358
Cancer Cell. 2014 May 12;25(5):563-73
pubmed: 24823636
Oncotarget. 2016 Aug 30;7(35):57367-57378
pubmed: 27384678
Cell Mol Life Sci. 2021 Mar;78(6):3021-3044
pubmed: 33230565
Strahlentherapie. 1979 Jan;155(1):39-43
pubmed: 760275
Int J Mol Med. 2013 Jul;32(1):195-202
pubmed: 23632739
Int J Radiat Biol. 2003 Jul;79(7):547-59
pubmed: 14530164
Oncogene. 1999 Nov 1;18(45):6158-62
pubmed: 10557107
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9851-6
pubmed: 21555554
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634515
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102
pubmed: 22251901
Radiother Oncol. 1983 Nov;1(2):167-78
pubmed: 6680221
Cell J. 2014 Fall;16(3):335-42
pubmed: 24611138
Cancers (Basel). 2011 Sep 30;3(4):3799-823
pubmed: 24213112
Nat Rev Clin Oncol. 2019 Nov;16(11):669-683
pubmed: 31189965
Cell J. 2017 Spring;19(Suppl 1):79-85
pubmed: 28580311
Radiat Environ Biophys. 2018 May;57(2):133-142
pubmed: 29453555
Mol Cancer Ther. 2018 Feb;17(2):393-406
pubmed: 28830984
Int J Hyperthermia. 2020;37(1):711-741
pubmed: 32579419
J Histochem Cytochem. 2002 Feb;50(2):197-204
pubmed: 11799138
Curr Med Chem. 2018;25(21):2465-2502
pubmed: 29345569
Eur J Cancer. 1977 Jan;13(1):23-8
pubmed: 844473
J Biol Chem. 2001 Jul 27;276(30):28546-53
pubmed: 11352915
Radiother Oncol. 2007 Jun;83(3):304-10
pubmed: 17517444
Annu Rev Biochem. 2005;74:739-89
pubmed: 15952902
J Biomol Screen. 2004 Jun;9(4):273-85
pubmed: 15191644
Annu Rev Biochem. 2015;84:435-64
pubmed: 25784053
Sci Rep. 2020 Feb 3;10(1):1653
pubmed: 32015396
Int J Mol Sci. 2017 Sep 15;18(9):
pubmed: 28914774
Cell. 2001 Dec 28;107(7):881-91
pubmed: 11779464
J Cell Physiol. 2012 Aug;227(8):2982-7
pubmed: 22105155
Cell Stress Chaperones. 2017 Jul;22(4):517-529
pubmed: 28144778
Sci Rep. 2017 Jun 19;7(1):3831
pubmed: 28630443
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
Int J Mol Sci. 2019 May 30;20(11):
pubmed: 31151143
Int J Hyperthermia. 2014 Mar;30(2):102-9
pubmed: 24571173
Arch Pharm Res. 2020 Jan;43(1):46-57
pubmed: 31993968
Int J Mol Sci. 2018 Sep 17;19(9):
pubmed: 30227629
Front Oncol. 2017 Jun 30;7:132
pubmed: 28713771
Int J Radiat Oncol Biol Phys. 1983 Mar;9(3):383-6
pubmed: 6841191
Int J Radiat Biol. 2007 Nov-Dec;83(11-12):849-71
pubmed: 18058370
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
Int J Cancer. 2014 Aug 15;135(4):968-80
pubmed: 24615356
Cold Spring Harb Perspect Biol. 2010 Dec;2(12):a004390
pubmed: 21123396
Int J Hyperthermia. 2014 Dec;30(8):531-9
pubmed: 25430985
Radiat Oncol. 2016 Feb 11;11:21
pubmed: 26868027
Cell J. 2017 Spring;19(Suppl 1):86-95
pubmed: 28580312
Int J Hyperthermia. 2008 Dec;24(8):613-22
pubmed: 18608577
Methods Mol Biol. 2018;1709:423-441
pubmed: 29177675
J Clin Invest. 2020 Feb 3;130(2):699-714
pubmed: 31845908
Cold Spring Harb Perspect Biol. 2012 Nov 01;4(11):
pubmed: 23125017
Int J Hyperthermia. 2016;32(1):41-9
pubmed: 26670625
Genes Dev. 1998 Dec 15;12(24):3788-96
pubmed: 9869631
Mol Pharmacol. 2014 Feb;85(2):345-56
pubmed: 24296859
Radiother Oncol. 2007 Jun;83(3):316-25
pubmed: 17531334
Genes Dev. 2008 Jun 1;22(11):1427-38
pubmed: 18519635
Cancers (Basel). 2019 Aug 16;11(8):
pubmed: 31426426
Invest New Drugs. 2018 Apr;36(2):278-287
pubmed: 29250742
Mol Cell. 2010 Oct 22;40(2):253-66
pubmed: 20965420
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):543-53
pubmed: 17980509
Tumour Biol. 2016 Jan;37(1):931-42
pubmed: 26260271
Annu Rev Biochem. 1986;55:1151-91
pubmed: 2427013
Ann Oncol. 2016 Jun;27(6):1116-1122
pubmed: 27022067

Auteurs

Oleg Chen (O)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.
Department of Cell Signaling, Institute of Cell Biology, National Academy of Sciences of Ukraine, 79005 Lviv, Ukraine.

Soňa Michlíková (S)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.

Lisa Eckhardt (L)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.

Marit Wondrak (M)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.

Adriana M De Mendoza (AM)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.
Physics Department, Pontificia Universidad Javeriana, Bogotá 110231, Colombia.

Mechthild Krause (M)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.
German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
Institute of Radiooncology-OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, 01328 Dresden, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany.

Damian D McLeod (DD)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.
School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing and Hunter Medical Research Institute, The University of Newcastle, Callaghan 2308, Australia.
School of Medicine and Health Sciences, Department of Cardiology, Carl von Ossietzky University of Oldenburg, 26129 Oldenburg, Germany.

Leoni A Kunz-Schughart (LA)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, 01307 Dresden, Germany.
National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany.

Classifications MeSH